Trials / Completed
CompletedNCT04926233
Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,371,146 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tiotropium bromide + Olodaterol | Tiotropium bromide + Olodaterol |
| DEVICE | Sp(t)iolto® Respimat® | Sp(t)iolto® Respimat® |
Timeline
- Start date
- 2019-11-15
- Primary completion
- 2020-04-14
- Completion
- 2020-04-14
- First posted
- 2021-06-15
- Last updated
- 2021-11-15
- Results posted
- 2021-07-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04926233. Inclusion in this directory is not an endorsement.